Subgroup analyses also revealed a difference in survival between the patients with and without FGFR1-amplified breast cancer in the hormone receptor-positive group (P = 0.001; Figure 4B), but not in the hormone receptor-negative group (P = 0.284; Figure 4C). Here, NR4A1 is linked to breast cancer.